Preoperative Tim‑3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer

Wang,Yang; Sun,Jintang; Gao,Wenjuan; Song,Bingfeng; Shao,Qianqian; Zhao,Lei; Zhang,Yun; Wang,Qingjie; Zhang,Yun; Qu,Xun

doi:10.3892/mmr.2017.6482

Preoperative Tim‑3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer

Authors:
- Yang Wang
- Jintang Sun
- Wenjuan Gao
- Bingfeng Song
- Qianqian Shao
- Lei Zhao
- Yun Zhang
- Qingjie Wang
- Xun Qu
View Affiliations

Affiliations: Department of Tumor Immunity, Institute of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: April 19, 2017 https://doi.org/10.3892/mmr.2017.6482
Pages: 3810-3818

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous research has indicated that T cell immunoglobulin and mucin domain 3 (Tim-3) serves an important regulatory role in lymphocytes and in several cancers. However, the association between Tim‑3 expression on various lymphocyte subsets and human colorectal cancer (CRC) has not been elucidated. The present study aimed to characterize Tim‑3 expression on peripheral lymphocytes, including cluster of differentiation CD3+CD56‑ T cells, CD3‑CD56+ natural killer (NK) cells and CD3+CD56+ natural killer T (NKT) cells, in patients with CRC. The frequency of T cells, NK cells and NKT cells expressing Tim‑3 was assessed by multicolor flow cytometry of peripheral blood collected from 36 preoperative CRC patients and 38 healthy donors. The expression of Tim‑3 on lymphocyte subsets from 53 postoperative blood samples of CRC patients was also analyzed. There were fewer circulating NK cells in patients with CRC compared with healthy controls (P=0.0027); NK cell expression of Tim‑3 was also significantly decreased (P=0.0239). The frequency of circulating NK cells and Tim‑3+ NK cells was negatively correlated with clinical cancer stage, compared with healthy controls, but not with other clinicopathological parameters or serum concentrations of CRC biomarkers. Furthermore, the expression of Tim‑3 in NK cells was higher in CRC patients without metastasis. Notably, NK cell Tim‑3 expression in CRC patients was significantly restored following surgical resection of the primary tumor. In conclusion, the present study indicates the presence of an altered frequency and expression of Tim‑3 in peripheral NK cells in CRC patients. Preoperative Tim‑3 expression on peripheral NK cells is correlated with differential staging in colorectal cancer, and may be useful as a serum biomarker.

View Figures

View References

1	Dalgleish AG and O'Byrne KJ: Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res. 84:231–276. 2002. View Article : Google Scholar : PubMed/NCBI
2	Shibata M, Nezu T, Kanou H, Abe H, Takekawa M and Fukuzawa M: Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol. 34:416–420. 2002. View Article : Google Scholar : PubMed/NCBI
3	Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 353:2654–2666. 2005. View Article : Google Scholar : PubMed/NCBI
4	Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H and Imamura M: Increased intratumor Valpha24-positive natural killer T cells: A prognostic factor for primary colorectal carcinomas. Clin Cancer Res. 11:7322–7327. 2005. View Article : Google Scholar : PubMed/NCBI
5	Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, et al: Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 112:1088–1097. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ling L, Zhao P, Yan G, Chen M, Zhang T, Wang L and Jiang Y: The frequency of Th17 and Th22 cells in patients with colorectal cancer at pre-operation and post-operation. Immunol Invest. 44:56–69. 2015. View Article : Google Scholar : PubMed/NCBI
7	Pawa N, Arulampalam T and Norton JD: Screening for colorectal cancer: Established and emerging modalities. Nat Rev Gastroenterol Hepatol. 8:711–722. 2011. View Article : Google Scholar : PubMed/NCBI
8	Murdoch C, Muthana M, Coffelt SB and Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar : PubMed/NCBI
9	Shi C and Pamer EG: Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 11:762–774. 2011. View Article : Google Scholar : PubMed/NCBI
10	Diederichsen AC, Hjelmborg Jv, Christensen PB, Zeuthen J and Fenger C: Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 52:423–428. 2003. View Article : Google Scholar : PubMed/NCBI
11	Hua W, Yuan A, Zheng W, Li C, Cui J, Pang Z, Zhang L, Li Z, Goll R and Cui G: Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas. Pathol Res Pract. 212:106–112. 2016. View Article : Google Scholar : PubMed/NCBI
12	Singh PP, Sharma PK, Krishnan G and Lockhart AC: Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep(Oxf). 3:289–297. 2015.PubMed/NCBI
13	Xu B, Yuan L, Gao Q, Yuan P, Zhao P, Yuan H, Fan H, Li T, Qin P, Han L, et al: Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget. 6:20592–21603. 2015. View Article : Google Scholar : PubMed/NCBI
14	Kuchroo VK, Dardalhon V, Xiao S and Anderson AC: New roles for TIM family members in immune regulation. Nat Rev Immunol. 8:577–580. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD and Zheng H: PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 5:e3302015. View Article : Google Scholar : PubMed/NCBI
16	Cai C, Xu YF, Wu ZJ, Dong Q, Li MY, Olson JC, Rabinowitz YM, Wang LH and Sun Y: Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma. World J Urol. 34:561–567. 2016. View Article : Google Scholar : PubMed/NCBI
17	da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I and Bhardwaj N: Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2:410–422. 2014. View Article : Google Scholar : PubMed/NCBI
18	Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, He J, Wu G, Liu X and Zhang Y: Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 29:635–641. 2015. View Article : Google Scholar : PubMed/NCBI
19	Edge SB, Byrd SR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer-Verlag; New York, NY: pp. 143–164. 2010
20	Golden-Mason L, Hurtado CE Waasdorp, Cheng L and Rosen HR: Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3. Clin Immunol. 158:114–125. 2015. View Article : Google Scholar : PubMed/NCBI
21	Anderson AC: Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 24:213–216. 2012. View Article : Google Scholar : PubMed/NCBI
22	Imai K, Matsuyama S, Miyake S, Suga K and Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet. 356:1795–1799. 2000. View Article : Google Scholar : PubMed/NCBI
23	Koda K, Saito N, Oda K, Seike K, Kondo E, Ishizuka M, Takiguchi N and Miyazaki M: Natural killer cell activity and distant metastasis in rectal cancers treated surgically with and without neoadjuvant chemoradiotherapy. J Am Coll Surg. 197:254–260. 2003. View Article : Google Scholar : PubMed/NCBI
24	Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M and Miyazaki M: Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 20:445–451. 2003. View Article : Google Scholar : PubMed/NCBI
25	Vivier E, Ugolini S, Blaise D, Chabannon C and Brossay L: Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 12:239–252. 2012. View Article : Google Scholar : PubMed/NCBI
26	Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF and Lanier LL: Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 119:3734–3743. 2012. View Article : Google Scholar : PubMed/NCBI
27	Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, et al: Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 119:3064–3072. 2012. View Article : Google Scholar : PubMed/NCBI
28	Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I, et al: Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 17:678–689. 2011. View Article : Google Scholar : PubMed/NCBI
29	Xu LY, Chen DD, He JY, Lu CC, Liu XG, Le HB, Wang CY and Zhang YK: Tim-3 expression by peripheral natural killer cells and natural killer T cells increases in patients with lung cancer-reduction after surgical resection. Asian Pac J Cancer Prev. 15:9945–9948. 2014. View Article : Google Scholar : PubMed/NCBI
30	Jost S, Moreno-Nieves UY, Garcia-Beltran WF, Rands K, Reardon J, Toth I, Piechocka-Trocha A, Altfeld M and Addo MM: Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection. Retrovirology. 10:742013. View Article : Google Scholar : PubMed/NCBI
31	Wang YR, Yan JX and Wang LN: The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer. J Cancer Res Ther. 10 Suppl:S307–S309. 2014. View Article : Google Scholar
32	Zhu Z, Chen Z, Chen C, Yang Z, Xuan W, Hou Y, Zuo Y and Ren S: Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma. Mol Clin Oncol. 2:139–145. 2014.PubMed/NCBI
33	Haddad AQ and Margulis V: Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol. 12:253–262. 2015. View Article : Google Scholar : PubMed/NCBI
34	Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI